|
|
|
|
|
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
/ Not yet recruiting临床1期IIT An Open, Single-arm, Multicenter Phase Ib Clinical Study of XH-30002 Capsule Combined With Afatinib Tablets for the Treatment of Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This study is an exploratory clinical trial and does not involve statistical assumptions or sample size estimation. the mainly purpose for the study is to evaluate the safety of XH-30002 capsule combined with afatinib tablets in the treatment of locally advanced or metastatic esophageal squamous cell carcinoma.
一项评价XH-30002胶囊口服给药在晚期实体瘤患者中的安全性、耐受性、药代动力学特征和初步疗效的Ⅰ期临床研究
观察XH-30002胶囊在晚期实体瘤患者中的安全性和耐受性,确定XH-30002胶囊单次及多次口服给药在晚期实体瘤患者中的最大耐受剂量(MTD)和/或II期推荐剂量(RP2D)。
100 项与 CDK4 x FLT3 x AXL 相关的临床结果
100 项与 CDK4 x FLT3 x AXL 相关的转化医学
0 项与 CDK4 x FLT3 x AXL 相关的专利(医药)